ClinicalTrials.gg
RecruitingNCT06678191STRENGTHUpdated Nov 22, 2024

Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting

An observational study in Asthma, Chronic Obstructive Pulmonary Disease (COPD) and Asthma Bronchiale, sponsored by Chiesi Hungary Ltd.. Recruiting at 45 sites in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-22.

Sponsored by Chiesi Hungary Ltd. (part of Chiesi Farmaceutici S.p.A.) · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Planned enrollment
5th of 15
800 · median 300
Started
2024
with 3 others
Observational
15 of 81
6 open now
Primary completion
2026-10
later than 4 of 10 live
Registered
71st of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 5th largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2024, is one of 15 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 71st registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients on GINA treatment Steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and quality of life. Also, there is scarcity of data regarding the phenotypes of asthmatics who benefit the most from the use of fixed triple combinations.

Read the detailed description

Study design Multicentre, national, non-interventional, prospective study evaluating the effectiveness of Trimbow 172/5/9 μg pMDI on symptom scores in 6 months after switch from previous LABA-high dose ICS containing treatment in asthmatics.

Dosage regimen and administration Name of the product: Trimbow 172 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution (henceforth abbreviated as Trimbow 172/5/9 μg pMDI). Each delivered dose (the dose leaving the mouthpiece) contains 172 μg of beclometasone dipropionate, 5 μg of formoterol fumarate dihydrate and 9 μg of glycopyrronium (as 11 μg glycopyrronium bromide). Each metered dose (the dose leaving the valve) contains 200 μg of beclometasone dipropionate, 6 μg of formoterol fumarate dihydrate and 10 μg of glycopyrronium (as 12.5 μg glycopyrronium bromide). The recommended dose is two inhalations twice daily. The maximum dose is two inhalations twice daily.

  1. Aim of the study (research objective)

    Primary objective:

    The main objective is to assess the effectiveness of BDP/FF/G 172/5/9 μg fixed triple combination in a real-world setting, with regards to improvements in symptom scores (ACT).

  2. Test sample and method, recruitment principle No patient recruitment will be performed. Eligible patients will be enrolled during the participating physicians' regular asthma patient management and patients' written informed consent. Patient inclusion will take place among patients having severe asthma and attending pulmonology outpatient clinics (the chosen study sites are attached as annexes to the study protocol), strictly at the time of the patients' visit. The planned number of patients is 800.
  3. Structure of the study In accordance with the requirements of non-interventional studies, the assignment of patients to Trimbow 172/5/9 μg pMDI therapy should be made independently of the study, and patients should only be considered for inclusion in the study after a prior therapeutic decision has been made by a pulmonologist. Patient enrolment can take place after the patient has been fully informed about the purpose of the study and all of its details, and the patient has read and signed the patient information leaflet and patient consent form, including any questions they may have. Once this has taken place, the data that would have been generated anyway during the outpatient examination of the patient in accordance with daily practice can be recorded. This is considered the first visit of the study (Visit 1). During this visit, the patient's main demographic data, information on comorbidities and concomitant medications, previous and current asthma therapies, asthma specific assessment (including ACT), exacerbation history, post-dose lung function values (if spirometry data is available), laboratory results (if a laboratory test is performed during the visit or was performed recently), results of other medical examinations (e.g., chest X-ray) if performed regardless of the study, maintenance and reliever inhaled \& non-inhaled therapies (former and new) baseline quality of life based on the asthma quality of life (EQ-5D-5L) questionnaire, and adherence to therapy based on Test of Adherence to Inhalers® (TAI-12) questionnaire are recorded. Patients will then attend two additional visits 30 days and 6 months after enrolment as per routine clinical practice (Visits 2 and 3). During these visits, data will also be recorded, once again, according to routine clinical practice. Assessing the usage of rescue medications and patient adherence are also planned with the use of electronic health record system (EESZT)-verified prescription dispensations (optional for investigators). Visit 4 will be a long-term follow-up to assess the exploratory endpoint of exacerbations rates.

    If the patient's maintenance therapy changes during the study as decided by the treating pulmonologist, and the patient is no longer receiving Trimbow 172/5/9 μg pMDI, the patient will be automatically excluded from this NIS. The fact of the therapy modification and its exact date must be recorded on the "current medication" form in the eCRF (electronic Case Report Form) of the next visit. If the change in therapy is related to a suspected adverse reaction, it should be reported separately on the eCRF platform in accordance with section 9 of this protocol ('Collection, recording and reporting of medication safety data').

    This NIS is open to all eligible patients according to the inclusion and exclusion criteria. Permitted concomitant treatments: allowed all medications according to local clinical practice (any non-inhalation therapy for asthma or other diseases) and reliever (short-acting bronchodilators) inhaled therapies for asthma. The data to be recorded will be detailed in the study data sheet that forms part of the protocol. The data is recorded in the eCRF (MrAgent - Medisol Development Ltd., see also at 10.1.) system, with consideration to the current professional and legal regulations.

  4. Start and duration of the study The first patient enrolment will take place after receiving approval from the National Public Health Center (NPHC), based on a beneficial assessment of the Medical Research Council of Hungary. The study is planned to start on September 16, 2024. Accordingly, first patient first visit (FPFV) is also planned to take place in September, 2024. The launch of the participating centres is planned in two waves, in the autumn of 2024 and in the spring of 2025. Each centre will have 12 months to enrol patients. After the last visit of the last patient (LPLV), centres will have one month to collect all missing data / correct any data flagged as queries during monitoring. Thus, the LPLV will take place on Oct 31, 2026 (primary endpoint) and 30 April, 2027 (exploratory endpoint), respectively. The study is planned to be concluded on August 31, 2027.
  5. Data to be recorded during the visits A total of 4 visits will be performed for the assessment of the primary and secondary endpoints during the study. The table below summarises the data collection to be carried out during the visits separately. The patient may be enrolled in the study and their data may only be recorded, if these data would also have been recorded in accordance with standard medical practice.

    • Visit 1: Time of enrolment - a normal visit, according to routine clinical practice. Informed consent and baseline patient characteristics will be collected.
    • Visit 2: 1 month after enrolment (± 2-3 workdays)
    • Visit 3: 6 months after enrolment (± 5-7 workdays)
    • Visit 4: 12 months after enrolment (± 10-15 days)
03

Conditions studied

  • Asthma, Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma Bronchiale

Keywords

  • Asthma therapy
  • Fixed triple inhalation treatment
  • Trimbow
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Asthma patients treated at GINA step 5, uncontrolled with ICS-LABA, containing high dose ICS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician-confirmed clinical diagnosis of asthma according to GINA guidelines and treated for at least 3 years before inclusion
  • Patients ≥ 18 years of age in ambulatory care
  • Uncontrolled asthma according to the physician's clinical assessment despite the use of

    1. LABA - high dose ICS OR
    2. LABA - high-dose ICS + LAMA multi-inhaler triple therapy for a minimum of three months.
  • Patients who are eligible for the use of Trimbow 172/5/9 μg pMDI according to the SmPC and the financing protocol for asthma

    1. At least on exacerbation, requiring systemic (oral or intravenous) in the previous 12 months
    2. Uncontrolled asthma (ACT≤15)
    3. \<80% at baseline
  • Inhaled asthma therapy was changed to Trimbow 172/5/9 μg pMDI no more than 1 week prior to OR on the day of study inclusion
  • Patient provided written, to study participation

Exclusion criteria

EXCLUSION CRITERIA:

  • Participation in any clinical trial within 30 days prior to enrolment
  • Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment
  • Another respiratory condition, apart from asthma or , that may interfere with the effectiveness of the treatment studied AND/OR another important clinical situation that may interfere with patient's compliance with the treatment.
  • Continuous use of oral (>5 mg prednisolone/day OR >4 mg methylprednisolone/day) OR intravenous CHMED_2024/01 Prof. Dr. Lilla Tamási 8(17)
  • Use of continuous oxygen therapy
  • Any malignant disease in the last 5 years
  • Tuberculosis (active or anamnestic)
  • Actual or previous use of biologics for asthma treatment in the past 12 months
  • All exclusion criteria listed in Trimbow 172/5/9 μg pMDI SmPC
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Asthmatic patients switched to Trimbow (BDP/FF/G 172/5/9 μg)

    Asthmatic patients who had been switched to BDP/FF/G 172/5/9 μg before study enrollment, due to uncontrolled asthma.

    Drug: BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg

Interventions

  • DrugBDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg

    In accordance with the requirements of non-interventional studies, the assignment of patients to Trimbow 172/5/9 μg pMDI therapy should be made independently of the study, and patients should only be considered for inclusion in the study after a prior therapeutic decision has been made by a pulmonologist.

06

What researchers measure

Primary outcomes

  1. Asthma control Test

    Change (improvement) of asthma control test (ACT) score, during the 6 months of treatment (Visit 3), compared to the score at baseline.

    Time frame: 6 months

  2. Asthma control Test 2

    • The percentage of patients achieving an improvement in asthma control test (ACT) score of 3 points (MCID, minimum clinically important difference) or more, after the 6 months treatment (Visit 3) compared to baseline.

    Time frame: 6 months

Secondary outcomes

  1. Asthma control test change

    The percentage of patients achieving an improvement according to asthma control levels (uncontrolled= ACT ≤15; partially controlled= 15\<ACT\<20; controlled 20≤ACT)

    Time frame: 6 months

  2. HRQoL

    Change in Health-related QoL was assessed by measuring the 5-level EuroQoL 5-dimension component (EQ-5D-5L) index score at Visit 3 (6 months), compared to the baseline visit 1 (Week 0), regarding the assessment of the impact of Asthma on the patient's quality of life.

    Time frame: 6 months

  3. Adherence

    Change in Test of Adherence to Inhalers® (TAI-12) score at Visit 3 (6 months) compared to baseline visit (Visit 1, week 0) regarding adherence to treatment with use of the Trimbow 172/5/9 μg pMDI.

    Time frame: 6 months

  4. Lung function

    Change in spirometric parameters: FEV1, FVC, FEV1/FVC, at Visit 3 (6 months), compared to the baseline Visit 1 (Week 0), with use of the Trimbow 172/5/9 μg pMDI.

    Time frame: 6 months

Other outcomes

  1. Exacerbations

    Changes in moderate and severe exacerbation rates at Visit 4 (12 months), compared to the baseline Visit 1 (Week 0), with use of the Trimbow 172/5/9 μg pMDI

    Time frame: 12 months

07

Study locations

45 of 45 sites recruiting
  • Kispesti Egészségügyi Intézet Tüdőgondozó, Ernyőképszűrő állomás
    Budapest, Hungary
    Recruiting
    • Brigitta Dombai, Dr. · Contact
    • Brigitta Dombai, Dr. · Sub investigator
    • Andrea BÍró, Dr. · Sub investigator
  • Országos Korányi Pulmonológiai Intézet (OKPI)
    Budapest, Hungary
    Recruiting
    • Zsuzsanna Csoma, Dr. · Contact
    • Zsuzsanna CSoma, Dr. · Principal investigator
  • Semmelweis Egyetem, Általános Orvostudományi Kar, Pulmonológiai Klinika
    Budapest, Hungary
    Recruiting
    • Lilla Tamási, Prof. · Contact
    • Noémi Eszes, Dr. · Sub investigator
    • Edit Hídvégi, Dr. · Sub investigator
    • Tamás Erdélyi, Dr. · Sub investigator
    • Lilla Tamási, Prof. · Principal investigator
  • Szent Kristóf Szakrendelő XI. Kerületi Tüdőgondozó
    Budapest, Hungary
    Recruiting
    • Ildikó Nádudvary, Dr. · Contact
    • Ildikó Nádudvary, Dr. · Sub investigator
    • Erzsébet Juhász, Dr. · Sub investigator
    • Katalin Major, Dr. · Sub investigator
  • Szent Kristóf Szakrendelő XXII. Kerületi Tüdőgondozó
    Budapest, Hungary
    Recruiting
    • Lívia Medek, Dr. · Contact
    • Lívia Medek, Dr. · Principal investigator
  • XVI. Kerület Kertvárosi Egészségügyi Szolgálata, Tüdőgyógyászat
    Budapest, Hungary
    Recruiting
    • Éva Tót, Dr. · Contact
    • Éva Tót, Dr. · Principal investigator
    • Márta Molnár, Dr. · Sub investigator
  • Békés Megyei Központi Kórház, 2. Tüdőgyógyászat szakrendelés - 1. rendelés
    Békéscsaba, Hungary
    Recruiting
    • Árpád Vincze, Dr. · Contact
    • Árpád Vincze, Dr · Sub investigator
    • Péter Martyin, Dr · Sub investigator
    • Károly Tébi, Dr · Sub investigator
  • Csornai Margit Kórház Tüdőbeteggondozó Intézet
    Csorna, Hungary
    Recruiting
    • Zoltán Bártfai, Dr · Contact
    • Zoltán Bártfai, Dr. · Principal investigator
  • DE Klinikai Központ, Tüdőgyógyászati Klinika
    Debrecen, Hungary
    Recruiting
    • László Brúgos, Dr · Contact
    • László Brúgos, Dr · Principal investigator
    • Angéla Mikáczó, Dr · Sub investigator
  • Debreceni Egyetem Kenézy Gyula Egyetemi Kórház Pulmonológiai Részleg
    Debrecen, Hungary
    Recruiting
    • Réka Keszthelyi, Dr. · Contact
    • Réka Keszthelyi, Dr. · Principal investigator
    • Éva Kalmár, Dr. · Sub investigator
  • Debreceni Egyetem Klinikai Központ Allergológiai Szakrendelés
    Debrecen, Hungary
    Recruiting
    • Erzsébet Takács, Dr. · Contact
    • Erzsébet Takács, Dr · Principal investigator
  • SZTE SZAKK Deszki Multidiszciplináris Centrum
    Deszk, Hungary
    Recruiting
    • Klára Szalontay, Dr. · Contact
    • Klára Szalontay, Dr. · Principal investigator
  • Dunakeszi-SZTK Nonprofit Kft. Tüdőgyógyászat
    Dunakeszi, Hungary
    Recruiting
    • Katalin Kontz, Dr. · Contact
    • Katalin Kontz, Dr. · Principal investigator
  • Vaszary Kolos Kórház Tüdőgondozó Esztergom
    Esztergom, Hungary
    Recruiting
    • Gabriella Horváth, Dr. · Contact
    • Gabriella Horváth, Dr. · Principal investigator
  • Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház
    Fehérgyarmat, Hungary
    Recruiting
    • Sándor Tóth, Dr. · Contact
    • Sándor Tóth, Dr. · Principal investigator
  • Békés Megyei Központi Kórház 1. Tüdőgyógyászat Szakrendelés
    Gyula, Hungary
    Recruiting
    • Árpád Vincze, Dr · Contact
    • Árpád Vincze, Dr. · Principal investigator
  • Bugát Pál Kórház Tüdőbeteg Gondozó Intézet
    Gyöngyös, Hungary
    Recruiting
    • Csilla Szabó, Dr · Contact
    • Csilla Szabó, Dr. · Sub investigator
    • Valéria Sípos, Dr. · Sub investigator
  • Petz Aladár Megyei Oktató Kórház
    Győr, Hungary
    Recruiting
    • Márta Czompó, Dr. · Contact
    • Márta Czompó, Dr. · Principal investigator
  • Hajduböszörmény ESZ-V Nonprofit Kft Tüdőgyógyászat
    Hajdúböszörmény, Hungary
    Recruiting
    • Gabriella Kiss, Dr. · Contact
    • Gabriella Kiss, Dr. · Principal investigator
  • Tüdőgondozó / Szent Erzsébet Kórház
    Jászberény, Hungary
    Recruiting
    • Ida Nagy, dr. · Contact
    • Ida Nagy, Dr. · Principal investigator
  • Szent Kereszt Kórház Kalocsa,Tüdőgyógyászati Szakrendelés
    Kalocsa, Hungary
    Recruiting
    • Szabolcs Körmendy, Dr. · Contact
    • Szabolcs Körmendy, Dr. · Principal investigator
  • Somogy Megyei Kaposi Mór Oktató Kórház
    Kaposvár, Hungary
    Recruiting
    • Éva Kuczkó, Dr. · Contact
    • Éva Kuczkó, Dr. · Principal investigator
  • Keszthelyi Kórház Tüdőgondozó
    Keszthely, Hungary
    Recruiting
    • Sándor Tehenes, Dr. · Contact
    • Sándor Tehenes, Dr. · Principal investigator
  • Kisteleki Egészségügyi Központi Nonprofit Kft.
    Kistelek, Hungary
    Recruiting
    • Ágnes Selypes, Dr. · Contact
    • Ágnes Selypes, Dr. · Principal investigator
  • Szent Damján Görögkatolikus Kórház Tüdőgyógyászati gondozó 1.
    Kisvárda, Hungary
    Recruiting
    • Miklós Kukuly, Dr. · Contact
    • Miklós Kukuly, Dr. · Principal investigator
  • Selye János Kórház Tüdőgyógyászati Szakellátás
    Komárom, Hungary
    Recruiting
    • Judit Schlezák, Dr. · Contact
    • Judit Schlezák, Dr. · Principal investigator
    • Éva Szenes, Dr. · Sub investigator
  • Kunszentmárton Városi Egészségügyi Központ Tüdőgyógyászat
    Kunszentmárton, Hungary
    Recruiting
    • Tibor Süveges, Dr. · Contact
    • Tibor Süveges, Dr. · Principal investigator
  • Szaplonczay Manó Marcali Kórház Tüdőgyógyászati Szakrendelés
    Marcali, Hungary
    Recruiting
    • Jakoob Maha, Dr. · Contact
    • Jakoob Maha, Dr. · Principal investigator
  • Karolina Kórház-Rendelőintézet Mosonmagyaróvár
    Mosonmagyaróvár, Hungary
    Recruiting
    • Erika Unger, Dr. · Contact
    • Erika Unger, Dr. · Principal investigator
  • Mátrai Gyógyintézet Légzőszervi szakrendelés
    Mátraháza, Hungary
    Recruiting
    • Magdolna Horváth, Dr. · Contact
    • Magdolna Horváth, Dr. · Principal investigator
  • Kanizsai Dorottya Kórház
    Nagykanizsa, Hungary
    Recruiting
    • Magdolna Tankó, Dr. · Contact
    • Magdolna Tankó, Dr. · Principal investigator
  • Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház
    Nyírbátor, Hungary
    Recruiting
    • Krisztina Alb, Dr. · Contact
    • Krisztina Alb, Dr. · Principal investigator
  • Szabolcs-Szatmár- Bereg Megyei Kórházak és Egyetemi Oktatókórház Megyei-Városi Tüdőgondozó
    Nyíregyháza, Hungary
    Recruiting
    • Ildikó Kerényi, Dr. · Contact
    • Ildikó Kerényi, Dr. · Principal investigator
    • Rozália Fráter, Dr. · Sub investigator
    • Katalin Kaposi, Dr. · Sub investigator
  • Orosházi Kórház Tüdőgondozó
    Orosháza, Hungary
    Recruiting
    • Erika Vecsey, Dr. · Contact
    • Erika Vecsesy, Dr. · Principal investigator
  • Margit Kórház Pásztó Tüdőgyógyászati Szakrendelés
    Pásztó, Hungary
    Recruiting
    • Margit Füleki, Dr. · Contact
    • Margit Füleki, Dr. · Principal investigator
  • Egyesített Egészségügyi Intézmények Tüdőgondozó
    Pécs, Hungary
    Recruiting
    • Ágnes Varga, Dr · Contact
    • Ágnes Varga, Dr. · Principal investigator
  • Sarkadi Kistérségi Járóbeteg Szakellátó Központ
    Sarkad, Hungary
    Recruiting
    • István Lopusnyik, Dr. · Contact
    • István Lopusnyik, Dr. · Principal investigator
  • Siófoki Kórház-Rendelőintézet Tüdőgondozó
    Siófok, Hungary
    Recruiting
    • Anna Bartha, Dr. · Contact
    • Anna Bartha, Dr. · Principal investigator
  • Csongrád Megyei Mellkasi Betegségek Szakkórháza, Tüdőgondozó Intézet
    Szeged, Hungary
    Recruiting
    • László Makk, Dr · Contact
    • László Makk, Dr. · Sub investigator
    • Edit Füzesi, Dr. · Sub investigator
    • András Imréné Mihály, Dr. · Sub investigator
  • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelőintézet Tüdőgyógyászati Szakrendelés
    Szolnok, Hungary
    Recruiting
    • Tibor Juhász, Dr. · Contact
    • Tibor Juhász, Dr. · Sub investigator
    • Ildikó Szeredai, Dr. · Sub investigator
  • Markusovszky Egyetemi Oktatókórház
    Szombathely, Hungary
    Recruiting
    • Krisztina Hajdú, Dr. · Contact
    • Krisztina Hajdú, Dr. · Principal investigator
  • Alba Szűrőközpont
    Székesfehérvár, Hungary
    Recruiting
    • Zsolt Vidák, Dr. · Contact
    • Zsolt Vidák, Dr · Principal investigator
  • Fejér Megyei Szent György Egyetemi Oktató Kórház, Tüdőbeteg Gondozó, Városkörnyék I. Szakrendelés Székesfehérvár
    Székesfehérvár, Hungary
    Recruiting
    • Nóra Ferenczy, Dr. · Contact
    • Nóra Ferenczy, Dr. · Principal investigator
  • Református Pulmonológiai Centrum, Törökbálint
    Törökbálint, Hungary
    Recruiting
    • Csilla Farkas, Dr. · Contact
    • Csilla Farkas, Dr. · Sub investigator
    • Eszter Őri, Dr. · Sub investigator
  • Zala Megyei Szent Rafael Kórház
    Zalaegerszeg, Hungary
    Recruiting
    • Márta Beke, Dr. · Contact
    • Márta Beke, Dr. · Sub investigator
    • Mária Steierlein, Dr. · Sub investigator
    • Zsuzsanna Vecsey, Dr. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — IDP is sole property of the sponsor and will only be eligible upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2026, 24 months after the start.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 24 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Nov 7, 2024
StartActual
Oct 24, 2024
Primary completionEst.
Oct 31, 2026
CompletionEst.
Aug 31, 2027
Last update
Nov 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06678191
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
Oct 24, 2024
Primary completion
Oct 31, 2026 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Nov 22, 2024

Study contacts

András Keglevich, Dr.
Contact
a.keglevich@chiesi.com
+36309788085
Balázs Sánta, Dr.
Contact
b.santa@chiesi.com
+36309948432

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion